ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "211: Biotech's catch-22, a $100 genome, & dealing with monkeypox"
Episode Synopsis
Will gene therapy ever live up to expectations? Can anyone break up the genomics monopoly? And is innovation actually bad for biotech? This week, health care strategist Jared Holz of Oppenheimer joins us to discuss the weekend's big oncology conference and what it will take to change Wall Street's dire view of the drug industry. We also discuss a weighty FDA meeting on gene therapy, the potential of a $100 genome, and how the expanding monkeypox outbreak is creating challenges for public health agencies.
More episodes of the podcast The Readout Loud
382: Biotech's year in review
18/12/2025
In God we trust